Evidence map›Paper›PMID 37082415›Full record

ReviewPostepy psychiatrii neurologii2022

Analysis of research on the effectiveness of using probiotics for children with autism spectrum disorders, in order to reduce the core and accompanying autism symptoms. Review of randomized clinical trials.

Ewa Brzóska-Konkol, Barbara Remberk, Anna Papasz-Siemienuk

Open access · diamondAbstract readReview
In one paragraph

Review in Postepy psychiatrii neurologii, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ewa Brzóska-KonkolInstitute of Psychiatry and Neurology, Warsaw, Poland.ORCID https://orcid.org/0000-0001-7597-465X
Barbara RemberkInstitute of Psychiatry and Neurology, Warsaw, Poland.ORCID https://orcid.org/0000-0001-7776-009X
Anna Papasz-SiemienukInstitute of Psychiatry and Neurology, Warsaw, Poland.
Institute of Psychiatry and Neurology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The prevalence of autism spectrum disorder (ASD) has increased tenfold over the last 40 years and the World Health Organization (WHO) has placed it alongside other globally occurring common illnesses, such as cancer, cardiovascular disorders and diabetes. As there are yet no effective methods for treating ASD, the most frequently used therapeutic interventions are psychological, psychosocial, rehabilitation and developmental support, which in combination aim to support patients and their families. Early intervention improves the prognosis, but usually a cure is impossible. Patient's lives are often burdened with social difficulties in contact with their families, peers and in education, particularly when other disorders, diseases or intellectual impairment are present, leading to undesirable behaviours, including aggression or self-aggression. Aim of the study was to review the literature available, so as to determine the effectiveness of probiotics used for treating core and accompanying symptoms of autism in patients diagnosed with ASD, with a particular focus on children and adolescents. Views: The randomised clinical trials available on the clinicaltrials.gov register (accessed on June 27 Conclusions: There are still no consistent outcomes in studies on the use of probiotics in children and adolescents with ASD, and the scope of existing studies is limited. Nevertheless, the authors considered it worthwhile to explore whether probiotic interventions can indeed reduce the severity of ASD-related symptoms and behaviours. Further studies are required on specific indications, duration of treatment and the effectiveness of interventions in the defined problem areas.

Indexed as

ASDAsperger’s syndrome (AS)microbiomprobiotic

Identifiers

PMID37082415
PMCPMC9881571
OpenAlexW4226484949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.